Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.27|
|52 Week High||US$1.01|
|52 Week Low||US$10.16|
|1 Month Change||-11.59%|
|3 Month Change||-19.59%|
|1 Year Change||288.18%|
|3 Year Change||-23.89%|
|5 Year Change||n/a|
|Change since IPO||-32.01%|
Recent News & Updates
We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ENTX||US Biotechs||US Market|
Return vs Industry: ENTX exceeded the US Biotechs industry which returned 17.1% over the past year.
Return vs Market: ENTX exceeded the US Market which returned 31.1% over the past year.
Stable Share Price: ENTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ENTX's weekly volatility has decreased from 28% to 8% over the past year.
About the Company
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures.
Entera Bio Fundamentals Summary
|ENTX fundamental statistics|
Is ENTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ENTX income statement (TTM)|
|Cost of Revenue||US$257.00k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.64|
|Net Profit Margin||-3,448.23%|
How did ENTX perform over the long term?See historical performance and comparison
Is Entera Bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ENTX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ENTX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ENTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ENTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ENTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ENTX is overvalued based on its PB Ratio (4.9x) compared to the US Biotechs industry average (2.9x).
How is Entera Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ENTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ENTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ENTX's revenue (87.7% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ENTX's revenue (87.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ENTX's Return on Equity is forecast to be high in 3 years time
How has Entera Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ENTX is currently unprofitable.
Growing Profit Margin: ENTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ENTX is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare ENTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ENTX has a negative Return on Equity (-73.15%), as it is currently unprofitable.
How is Entera Bio's financial position?
Financial Position Analysis
Short Term Liabilities: ENTX's short term assets ($27.9M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: ENTX's short term assets ($27.9M) exceed its long term liabilities ($275.0K).
Debt to Equity History and Analysis
Debt Level: ENTX is debt free.
Reducing Debt: ENTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ENTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ENTX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 21.2% each year.
What is Entera Bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ENTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ENTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ENTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ENTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Spiros Jamas (60 yo)
Dr. Spiros Jamas, Sc D., serves as the Chief Executive Officer & Director of Entera Bio Ltd since January 4, 2021. He served as the Chief Executive Officer and President at Tempero Pharmaceuticals, Inc. fr...
Experienced Management: ENTX's management team is considered experienced (2.3 years average tenure).
Experienced Board: ENTX's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.7%.
Entera Bio Ltd.'s employee growth, exchange listings and data sources
- Name: Entera Bio Ltd.
- Ticker: ENTX
- Exchange: NasdaqCM
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$122.796m
- Shares outstanding: 28.76m
- Website: https://www.enterabio.com
Number of Employees
- Entera Bio Ltd.
- Kiryat Hadassah Minrav Building
- Fifth Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 23:06|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.